Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Harmine is a naturally occurring β-carboline alkaloid found in several plants, notably *Peganum harmala* (Syrian rue) and *Banisteriopsis caapi*, the latter being a key ingredient in the psychoactive brew ayahuasca. Chemically, it is known as 7-methoxy‑1‑methyl‑β‑carboline. Harmine acts primarily as a reversible inhibitor of monoamine oxidase A (MAO-A), thereby increasing levels of monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine[2][1]. It also inhibits dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and related kinases[8][1]. Harmine has been studied for its hallucinogenic properties at higher doses and has shown various pharmacological activities including anti-tumor, antimicrobial, antiplasmodial, antioxidant, neuroprotective effects, and potential antidepressant activity[5][9]. Historically investigated for Parkinson’s disease treatment in the early to mid 20th century[2], it remains an investigational compound with no current regulatory approval for medical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on harmine.